Teva Pharma (TEVA) Reports In-Line Q4 EPS, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
February 8, 2023 7:00 AM ESTTEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005167/en/
Q4 and FY 2022 highlights:Â
Q4... More
